education · health · income_security_and_social_services · HHS-NIH11

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)

National Institutes of Health · PAR-25-111

Closed

Deadline

July 6, 2026

GRANTQUICK SUMMARYPlain-English Overview

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional). National Institutes of Health. The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant women, lactating women, and children through the development of novel tools, models, and other technologies that could have a direct clinical... Funding amounts not specified.

Who Should Apply

Nonprofits (non-501c3), Public And Indian Housing Authorities, For-profit organizations, City/township governments, Federally Recognized Native American Tribal Governments (+10 more)

Who Should NOT Apply

Organizations not matching the eligible applicant types listed above

Key Requirements (Plain English)

•Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Isl...
•Deadline: 2026-07-06

💡 GrantQuick Tip

Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.

Competitiveness: Moderate to high — federal grants are always competitive

What This Grant Funds

The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant women, lactating women, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating women, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating women, fetuses, neonates, and children, including those with disabilities.

Attachments

PDF

PAR-25-111 Full Announcement Text

PAR-25-111-Full-Announcement.html

Who Can Apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Eligible Applicant Types

Nonprofits without 501(c)(3)Public And Indian Housing AuthoritiesFor-Profit OrganizationsCity/Township GovernmentsFederally Recognized Tribal GovernmentsOther Tribal OrganizationsState GovernmentsSmall BusinessesPublic Colleges & UniversitiesSpecial District GovernmentsIndependent School DistrictsPrivate Colleges & UniversitiesCounty Governments501(c)(3) NonprofitsOther (see NOFO for details)

Funding Details

Cost Sharing Required?: No
Funding Instrument: grant

Key Dates

Posted: November 18, 2024

Application Deadline: July 6, 2026 (0 days remaining)

Agency Contact

NIH Grants Information grantsinfo@nih.gov

grantsinfo@nih.gov

Ready to apply?

View the full NOFO and submit your application on Grants.gov

View on Grants.gov